ROCHESTER — Mayo Clinic and GE HealthCare will conduct research on an emerging treatment for prostate cancer and how that treatment can become more personalized to each patient, the two ...

New research has identified specific blood-based biomarkers that can predict the failure of prostate cancer treatment in both hormone-sensitive and castration-resistant patients. The study published ...

Most prostate cancers rely on male sex hormones, known as androgens, to grow. As a result, standard treatment focuses on lowering androgen levels or blocking their activity, but many tumors eventually ...

A study found that spop mutations increase prostate cancer sensitivity to ferroptosis, while chd1 deletions reduce vulnerability. Statins restored sensitivity in preclinical models, suggesting ...

New technologies can potentially save lives by helping identify prostate cancer earlier, and transforming the way doctors detect and track cancerous cells. Prostate cancer is the most common cancer ...

A large analysis suggests that a multivariable risk assessment tool, called Stockholm3, can detect substantially more ...

For many men, a prostate cancer scare starts with one number. A PSA result comes back high, and ...

An implantable microdevice safely delivered multiple drugs directly into prostate cancer lesions, enabling assessment of tumor-specific responses. All 14 patients successfully underwent robot-assisted ...